Previous studies have shown that CPT can reduce the activation of caspase-1 activity and the secretion of IL-1β in mouse models of NLRP3 inflammasome-mediated diseases such as endotoxemia syndrome and nonalcoholic steatohepatitis (NASH) [6]. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatohepatitis.